The 2021 CADP and Prohibited List Are Now in Effect
Courtesy of The Canadian Centre For Ethics In Sport (Originally Posted January 5, 2021 https://cces.ca/news/2021-cadp-and-prohibited-list-are-now-effect)
(Ottawa, Ontario – January 5, 2021) – The Canadian Centre for Ethics in Sport (CCES) reminds the Canadian sport community that two updated documents, the 2021 Canadian Anti-Doping Program (CADP) and the World Anti-Doping Agency’s (WADA) 2021 Prohibited List, came into effect January 1, 2021.
The CADP is compliant with the 2021 World Anti-Doping Code (the Code), which also came into effect on January 1. The CADP incorporates the Code and all mandatory International Standards, including the Prohibited List, which is the standard that identifies which substances and methods are prohibited in sport. The List is updated by WADA annually.
While the majority of the changes to the 2021 CADP focus on improvements to make the rules more effective, the CADP fully incorporates the new Athletes’ Anti-Doping Rights Act and commits to upholding the recommended rights outlined within. The CCES is a staunch supporter of the harmonization of global rules, which ensure a level playing field for Canadian athletes no matter where they compete, and of athletes’ right to compete in clean, fair and ethical sport.
2021 CADP reference documents
Major modifications to the Prohibited List
Substances of Abuse: A new article to the 2021 World Anti-Doping Code and Prohibited List identifies cocaine, diamorphine (heroin), methylenedioxymethamphetamine (MDMA/“ecstasy”) and tetrahydrocannabinol (THC) as substances of abuse. If an athlete can demonstrate that the use of any of these four substances was out-of-competition and unrelated to sport performance, the suspension imposed will be three months and may be reduced to one month if the athlete satisfactorily completes a Substance of Abuse treatment program approved by the CCES.
S3 – Beta-2 Agonists: Vilanterol was changed from a prohibited substance to a threshold substance. Inhaled vilanterol is now permitted up to the manufacturer’s maximum recommended dose. The dose is expressed as the metered dose of 25 micrograms which is equivalent to a delivered dose of 22 micrograms.
Glucocorticoids: A major modification for glucocorticoids will come into effect on January 1, 2022. As of that date, all injectable routes of administration for glucocorticoids will be prohibited in-competition. Implementation in 2022 will allow sport authorities adequate time to develop educational tools for athletes, and for medical and support personnel to address the safe use of glucocorticoids for clinical purposes within anti-doping.
Athletes are cautioned to exercise a high degree of care with regards to the use of medications, supplements and sport nutrition products. The following resources help athletes determine which medications are prohibited in sport. Athletes who are prescribed a prohibited medication to treat an illness or condition can apply for a medical exemption. These resources are up to date and reflect the new List:
- Global DRO
- Email: firstname.lastname@example.org
- Toll-free line: 1-800-672-7775
- Medical Exemption Wizard
- CCES Supplements webpage
- NSF International Certified for Sport® product database
- 2021 World Anti-Doping Code
- Athletes’ Anti-Doping Rights Act
- 2021 Prohibited List
- Summary of Major Modifications and Explanatory Notes
- 2021 Monitoring Program
About the CCES
The CCES is an independent, national, not-for-profit organization with a responsibility to administer the Canadian Anti-Doping Program. We recognize that true sport can make a great difference for individuals, communities and our country. The CCES acknowledges funding, in part, from the Government of Canada. We are committed to making sport better by working collaboratively to activate a values-based and principle-driven sport system; protecting the integrity of sport from the negative forces of doping and other unethical threats; and advocating for sport that is fair, safe and open to everyone.
For further information, please contact:
Corporate Communications Manager
+1 613-521-3340 x3233